Acrivon Therapeutics (ACRV) legal chief has 217 shares withheld for taxes

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine share disposition related to taxes. On the transaction date, 217 shares of common stock were withheld by the company at a price of $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. After this tax-withholding disposition, she held 33,679 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2026		F(1)		217	D	$1.63	33,679	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Mary Miller?

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller had 217 common shares withheld at $1.63 per share to cover mandatory tax withholding on vesting restricted stock units, leaving her with 33,679 directly held shares.

Was the Acrivon Therapeutics (ACRV) insider transaction an open-market sale?

No, the transaction was not an open-market sale. The 217 Acrivon Therapeutics shares were withheld by the issuer to satisfy mandatory tax withholding when restricted stock units vested, a common administrative disposition rather than a discretionary sale.

How many Acrivon Therapeutics (ACRV) shares were involved in Mary Miller’s tax-withholding event?

The event involved 217 Acrivon Therapeutics common shares. These shares were withheld by the company to meet tax obligations triggered by the vesting of restricted stock units, as described in the filing footnote.

How many Acrivon Therapeutics (ACRV) shares does Mary Miller hold after this Form 4?

After the reported tax-withholding disposition, Mary Miller directly holds 33,679 Acrivon Therapeutics common shares. This figure reflects her ownership following the withholding of 217 shares to cover mandatory tax liabilities on vested restricted stock units.

What does transaction code “F” mean in the Acrivon Therapeutics (ACRV) Form 4?

Transaction code “F” indicates shares were used to pay an exercise price or tax liability. In this Acrivon Therapeutics filing, 217 shares were withheld by the issuer to satisfy mandatory tax withholding when restricted stock units vested.